Wall Street Snaps up Drug Companies Offering Hopes of Coronavirus Drug
Codagenix starts human study of COVID-19 vaccine; further Sputnik data unveiled | 2020-12-14 | BioWorld
Serum Institute claims COVID-19 vaccine to be market ready by 2022 - BusinessToday
Serum Institute to manufacture US-based biotech firm Codagenix's COVID-19 vaccine - BusinessToday
Coronavirus: Both a threat and opportunity for India
A billion-plus covid-19 shots in 2021. Can Serum Institute do it?
Codagenix Company Profile: Valuation & Investors | PitchBook
Codagenix Eyes '23 Nasal RSV Vaccine Readout As GSK, Pfizer Set To Establish Lead :: Scrip
Codagenix Inc. on LinkedIn: We would like to highlight the incredible work of our CSO, Dr. Steffen…
The pandemic pipeline
A new approach to a Covid-19 nasal vaccine shows early promise | CNN
Coronavirus Vaccine in Works From Jim Simons-Backed Codagenix
Codagenix Announces Close of $25 million Extension of Series B
Codagenix uses synthetic biology and ML in vaccine development
Bumper year ahead for firm selling Covid tests to NHS
Platform-Specific Risk Assessment of SARS-CoV-2 Vaccines Using FMEA
Nasal COVID-19 vaccines help the body prepare for infection right where it starts – in your nose and throat
RSV vaccine player Codagenix snags $3M in public and private investment | Fierce Pharma
Inside India's Vaccine Ecosystem - BusinessToday - Issue Date: Dec 13, 2020
Stock-outs & silver linings - The Hindu BusinessLine
Long Island biotech lands $25M funding from Indian partner, others - Newsday
Home | Codagenix
